Pharma Exclusives Pressreleases
Calquence plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma
Friday, January 17, 2025AstraZenecas Calquence acalabrutinib in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma MCL who are ineligible for autologous hematopoietic ste...
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel
Monday, January 13, 2025Teva Pharmaceuticals International GmbH a subsidiary of Teva Pharmaceutical Industries Ltd today announced that it has entered into a strategic collaboration with Klinge Biopharma GmbH Klinge and Formycon AG FSE FYB for the semiexclusive commercializ...
BlueRock Therapeutics advances investigational cell therapy bemdaneprocel for treating Parkinson’s disease to registrational Phase III clinical trial
Monday, January 13, 2025Bayer AG and BlueRock Therapeutics LP a clinicalstage cell therapy company and wholly owned subsidiary of Bayer AG today announced plans to initiate a Phase III clinical trial for bemdaneprocel its investigational cell therapy for Parkinsons disease...
Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
Monday, January 13, 2025AstraZeneca and Daiichi Sankyos Biologics License Application BLA for datopotamab deruxtecan DatoDXd has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth fact...
Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies
Friday, January 10, 2025Bayer a global leader in radiology today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane an investigational gadoliniumbased contrast agent GBCA for use in magnetic resonanc...
Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale
Wednesday, January 08, 2025Boehringer Ingelheim BioXcellence and Sutro Biopharma Inc today announced that they successfully applied Sutros proprietary cellfree expression technology on a commercial scale to manufacture luveltamab tazevibulin luvelta Sutros Tubulin FRtargeting
Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases
Wednesday, January 08, 2025Novo Nordisk AS and Valo Health Inc today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity type diabetes and cardiovascular disease based on Valos extensive human dataset and computation pow...
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
Tuesday, December 31, 2024Immedica Pharma AB Immedica a leading global rare disease company and Marinus Pharmaceuticals Inc a pharmaceutical company committed to improving the lives of patients with seizure disorders today announced that they have entered into an agreement an...
Immunovia discovery study published in top protein research journal
Friday, December 20, 2024Immunovia the pancreatic cancer diagnostics company today announced the peerreviewed publication of the discovery study conducted by Immunovia to identify protein biomarkers for its nextgeneration pancreatic cancer test
Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease
Thursday, December 19, 2024Roche announced today results from the Phase IIb PADOVA study investigating prasinezumab in people with earlystage Parkinsons disease treated for a minimum of months while on stable symptomatic treatment Prasinezumab showed potential clinical effic...
